{
    "clinical_study": {
        "@rank": "132786", 
        "arm_group": {
            "arm_group_label": "TS-1/Cisplatin", 
            "arm_group_type": "Experimental", 
            "description": "single arm"
        }, 
        "brief_summary": {
            "textblock": "Objectives:\n\n        1. Primary Objective:\n\n           To bridge the data of efficacy in term of overall response rate of TS-1 plus cisplatin\n           in Taiwanese advanced NSCLC patients from that gained from Japanese population\n\n        2. Secondary Objectives:\n\n      A.  To assess progression free survival B.  To assess overall survival C.  To bridge the\n      safety profile by assessing the toxicities and tolerability"
        }, 
        "brief_title": "A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small-cell Lung Cancer (NSCLC)", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  presence of at least one measurable disease\n\n          -  performance status of ECOG 0, 1\n\n          -  age between 20 and 74 years at registration\n\n          -  life expectancy of at least 12 weeks\n\n          -  ability to take the oral study medication (TS-1)\n\n          -  voluntarily signed the written informed consent form.\n\n        Exclusion Criteria:\n\n          -  other malignancy with the exception of curative treated non-melanoma skin cancer or\n             cervical carcinoma in situ within 5 years prior to the entry of study\n\n          -  previously received chemotherapy or therapy with systemic anti-tumor effect\n\n          -  significant co-morbid medical conditions, including, but not limited to , heart\n             failure, renal failure, hepatic failure, hemorrhagic peptic ulcer, mechanical or\n             paralytic ileus, or poorly controlled diabetes\n\n          -  fertile women of child-bearing potential unless using a reliable and appropriate\n             contraceptive method throughout the treatment period and for three months following\n             cessation of treatment\n\n          -  Presence of mental disease or psychotic manifestation\n\n          -  Participation in another clinical trial with any investigational drug within 30 days\n             prior to entry\n\n          -  judged ineligible by physicians for participation in the study due to safety concern."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01874678", 
            "org_study_id": "TTYTG0904"
        }, 
        "intervention": {
            "arm_group_label": "TS-1/Cisplatin", 
            "intervention_name": "TS-1/Cisplatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Cisplatin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 8, 2014", 
        "link": {
            "description": "TFDA", 
            "url": "http://www.fda.gov.tw/TC/index.aspx"
        }, 
        "location": [
            {
                "contact": {
                    "email": "albertla@ms8.hinet.net", 
                    "last_name": "Chun-Liang Lai, M.D.", 
                    "phone": "05-264-8000", 
                    "phone_ext": "5246"
                }, 
                "facility": {
                    "address": {
                        "city": "Chiayi", 
                        "country": "Taiwan"
                    }, 
                    "name": "Dalin Tzu Chi General Hospital"
                }, 
                "investigator": {
                    "last_name": "Chun-Liang Lai, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ed102746@edah.org.tw", 
                    "last_name": "Yu-Feng Wei, M.D.", 
                    "phone": "07-615-0011", 
                    "phone_ext": "5057"
                }, 
                "facility": {
                    "address": {
                        "city": "Kaohsiung", 
                        "country": "Taiwan"
                    }, 
                    "name": "E-Da Hospital"
                }, 
                "investigator": {
                    "last_name": "Yu-Feng Wei, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "derrick.hsia@msn.hinet.net", 
                    "last_name": "Te-Chun Hsia, M.D.", 
                    "phone": "04-22062121", 
                    "phone_ext": "1251"
                }, 
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan"
                    }, 
                    "name": "China Medical University Hospital"
                }, 
                "investigator": {
                    "last_name": "Te-Chun Hsia, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "august@vghtc.gov.tw", 
                    "last_name": "Gee-Chen Chang, M.D.", 
                    "phone": "04-23592525", 
                    "phone_ext": "3256"
                }, 
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan"
                    }, 
                    "name": "Taichung Veterans General Hospital"
                }, 
                "investigator": {
                    "last_name": "Gee-Chen Chang, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ymchen@vghtpe.gov.tw", 
                    "last_name": "Yuh-Min Chen, M.D.", 
                    "phone": "02-2871-2121", 
                    "phone_ext": "3150"
                }, 
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }, 
                    "name": "Taipei Veterans General Hospital"
                }, 
                "investigator": {
                    "last_name": "Yuh-Min Chen, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer", 
        "overall_contact": {
            "email": "ymchen@vghtpe.gov.tw", 
            "last_name": "Yuh-Min Chen, M.D.", 
            "phone": "02-2871-2121", 
            "phone_ext": "3150"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Taiwan Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess overall response rate", 
            "measure": "overall response rate", 
            "safety_issue": "No", 
            "time_frame": "2 year"
        }, 
        "reference": [
            {
                "PMID": "21079147", 
                "citation": "Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Miyazaki M, Tamura K, Kurata T, Fukuoka M, Nakagawa K. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-na\u00efve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol. 2010 Dec 20;28(36):5240-6. doi: 10.1200/JCO.2010.31.0326. Epub 2010 Nov 15."
            }, 
            {
                "PMID": "15585618", 
                "citation": "Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, Niitani H. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res. 2004 Dec 1;10(23):7860-4."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01874678"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To assess progression free survival To assess overall survival To bridge the safety profile by assessing the toxicities and tolerability", 
            "measure": "To assess progression free survival To assess overall survival To bridge the safety profile by assessing the toxicities and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "2 year"
        }, 
        "source": "TTY Biopharm", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TTY Biopharm", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}